LV13544B - Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium - Google Patents

Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium Download PDF

Info

Publication number
LV13544B
LV13544B LVP-05-95A LV050095A LV13544B LV 13544 B LV13544 B LV 13544B LV 050095 A LV050095 A LV 050095A LV 13544 B LV13544 B LV 13544B
Authority
LV
Latvia
Prior art keywords
meldonium
azt
pharmaceutical composition
oct
content
Prior art date
Application number
LVP-05-95A
Other languages
English (en)
Latvian (lv)
Inventor
Vija Klusa
Sergejs Isajevs
Jolanta Pupure
Juris Rumaks
Valentina Gordjusina
Immanuels Taivans
Ivars Kalvins
Original Assignee
Grindeks As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37442067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV13544(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grindeks As filed Critical Grindeks As
Priority to LVP-05-95A priority Critical patent/LV13544B/lv
Priority to PCT/LV2006/000005 priority patent/WO2007021164A1/en
Priority to EEP200800014A priority patent/EE05529B1/xx
Priority to JP2008526897A priority patent/JP5027809B2/ja
Priority to AT06783790T priority patent/ATE493123T1/de
Priority to CN2006800298828A priority patent/CN101252925B/zh
Priority to UAA200803268A priority patent/UA90162C2/ru
Priority to ES06783790T priority patent/ES2361185T3/es
Priority to US11/990,285 priority patent/US7700576B2/en
Priority to DE602006019293T priority patent/DE602006019293D1/de
Priority to EP06783790A priority patent/EP1933823B1/en
Priority to ARP060103527A priority patent/AR066995A1/es
Priority to PE2006000983A priority patent/PE20070233A1/es
Priority to UY29751A priority patent/UY29751A1/es
Priority to HN2006029085A priority patent/HN2006029085A/es
Priority to SV2006002655A priority patent/SV2007002655A/es
Publication of LV13544B publication Critical patent/LV13544B/lv
Priority to LT2008003A priority patent/LT5524B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LVP-05-95A 2005-08-15 2005-08-15 Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium LV13544B (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
LVP-05-95A LV13544B (en) 2005-08-15 2005-08-15 Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium
EEP200800014A EE05529B1 (et) 2005-08-15 2006-08-08 Ravimikoostis, mis on valmistatud p””rdtranskriptaasi inhibiitori ja meldooniumi baasil
US11/990,285 US7700576B2 (en) 2005-08-15 2006-08-08 Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium
EP06783790A EP1933823B1 (en) 2005-08-15 2006-08-08 Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium
JP2008526897A JP5027809B2 (ja) 2005-08-15 2006-08-08 逆転写酵素阻害剤およびメルドニウムに基づく医薬組成物
AT06783790T ATE493123T1 (de) 2005-08-15 2006-08-08 Pharmazeutische zusammensetzung auf basis eines reversen transkriptase-hemmers und meldonium
CN2006800298828A CN101252925B (zh) 2005-08-15 2006-08-08 以逆转录酶抑制剂和美度铵为基础的药物组合物
UAA200803268A UA90162C2 (ru) 2005-08-15 2006-08-08 Фармацевтическая композиция на основе ингибитора обратной транскриптазы и мелдония
ES06783790T ES2361185T3 (es) 2005-08-15 2006-08-08 Composición farmacéutica basada en inhibidor de la transcriptasa inversa y meldonio.
PCT/LV2006/000005 WO2007021164A1 (en) 2005-08-15 2006-08-08 Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium
DE602006019293T DE602006019293D1 (de) 2005-08-15 2006-08-08 Pharmazeutische zusammensetzung auf basis eines reversen transkriptase-hemmers und meldonium
ARP060103527A AR066995A1 (es) 2005-08-15 2006-08-11 Composicion farmeceutica sobre la base de inhibidor de transcriptasa inversa y meldonio
UY29751A UY29751A1 (es) 2005-08-15 2006-08-14 Composicion farmaceutica basada en el inhibidor de la transcriptasa inversa y meldonio
PE2006000983A PE20070233A1 (es) 2005-08-15 2006-08-14 Composiciones farmaceuticas en base a inhibidores de transcriptasa inversa y meldonium
HN2006029085A HN2006029085A (es) 2005-08-15 2006-08-15 Compuestos farmaceuticos a base de un inhibidor de transcriptasa reversa y meldonio
SV2006002655A SV2007002655A (es) 2005-08-15 2006-08-15 Composición farmacéutica sobre la base de inhibidor de transcriptasa inversa y meldonio
LT2008003A LT5524B (lt) 2005-08-15 2008-01-18 Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-05-95A LV13544B (en) 2005-08-15 2005-08-15 Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium

Publications (1)

Publication Number Publication Date
LV13544B true LV13544B (en) 2007-05-20

Family

ID=37442067

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-05-95A LV13544B (en) 2005-08-15 2005-08-15 Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium

Country Status (17)

Country Link
US (1) US7700576B2 (es)
EP (1) EP1933823B1 (es)
JP (1) JP5027809B2 (es)
CN (1) CN101252925B (es)
AR (1) AR066995A1 (es)
AT (1) ATE493123T1 (es)
DE (1) DE602006019293D1 (es)
EE (1) EE05529B1 (es)
ES (1) ES2361185T3 (es)
HN (1) HN2006029085A (es)
LT (1) LT5524B (es)
LV (1) LV13544B (es)
PE (1) PE20070233A1 (es)
SV (1) SV2007002655A (es)
UA (1) UA90162C2 (es)
UY (1) UY29751A1 (es)
WO (1) WO2007021164A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021588B1 (ru) * 2009-06-25 2015-07-30 Тетра Сиа Бетаиновые соли ацетилсалициловой кислоты
LV14848B (lv) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompoz&imacr;cija trimetilam&imacr;na-N-oks&imacr;da l&imacr;me&ncedil;a pazemin&amacr;&scaron;anai

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU997646A1 (ru) 1978-11-27 1983-02-23 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Кормова добавка
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5130421A (en) 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IT1255039B (it) 1992-03-11 1995-10-13 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina.

Also Published As

Publication number Publication date
CN101252925A (zh) 2008-08-27
LT2008003A (en) 2008-07-25
JP2009504731A (ja) 2009-02-05
UY29751A1 (es) 2007-03-30
UA90162C2 (ru) 2010-04-12
DE602006019293D1 (de) 2011-02-10
WO2007021164A1 (en) 2007-02-22
US7700576B2 (en) 2010-04-20
AR066995A1 (es) 2009-09-30
ES2361185T3 (es) 2011-06-14
HN2006029085A (es) 2007-11-16
EE05529B1 (et) 2012-04-16
EP1933823B1 (en) 2010-12-29
JP5027809B2 (ja) 2012-09-19
EP1933823A1 (en) 2008-06-25
ATE493123T1 (de) 2011-01-15
EE200800014A (et) 2008-06-16
SV2007002655A (es) 2007-04-12
US20090137522A1 (en) 2009-05-28
CN101252925B (zh) 2012-04-25
PE20070233A1 (es) 2007-06-08
LT5524B (lt) 2008-10-27

Similar Documents

Publication Publication Date Title
ES2433476T3 (es) Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
Desager Clinical pharmacokinetics of ticlopidine
JP6153281B1 (ja) 細胞内ａｔｐ増強剤
PT1171137E (pt) Utilização de triacetiluridina para o tratamento de perturbações mitocondriais
BE1004168A3 (fr) Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv.
CN107920577A (zh) 协同饮料组合物
Wood et al. Drug-induced psychosis and depression in the elderly
Das et al. RETRACTED Redox regulation of angiotensin II preconditioning of the myocardium requires MAP kinase signaling
JP2024016228A (ja) アセトアミノフェン（ａｐａｐ）によって引き起こされる毒性を予防、低減または根絶するための方法および組成物
LV13544B (en) Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium
US6040346A (en) Use of L-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs
JP2022544718A (ja) 敗血症性心筋症を治療するための組成物および方法
Lemberg et al. Tolerabilities of antiretrovirals in paediatric HIV infection
US9259411B2 (en) Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
Breglia et al. Effect of selected amino acids on ethanol toxicity in rats
US11826334B2 (en) Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus
CA2878190A1 (en) Pharmaceutical composition for reducing the trimethylamine n-oxide level
Wheeler et al. Zidovudine‐induced diaphragmatic contractile dysfunction: Impact of an antioxidant diet
Sikora et al. From Gym to Medicine: Creatine Uses Beyond Athletic Performance
CN116808224A (zh) 用于治疗血管疾病的化合物组合
Fava et al. S-adenosyl-L-methionine as an Antidepressant Results of a MEDLINE Search by, Ivan Goldberg, MD
Growdon et al. Choline administration to patients with Huntington’s disease or tardive dyskinesia
CN1223582A (zh) 用噻唑烷酮治疗和预防神经变性疾病的方法
Germanyuk et al. General pharmacology and pharmacology of the drugs affecting mediatory processes, vegetative and central nervous systems
Sanders et al. Induction of thymic lymphoma in mice administered the dideoxynucleoside ddC